Proteostasis Therapeutics Inc. plans to offer 7 million common shares in an underwritten public offering.
The company also plans to grant underwriters a 30-day option to buy up to an additional 1,050,000 shares, or up to 15% of the offering size.
Leerink Partners LLC and RBC Capital Markets LLC are acting as joint book-running managers for the offering, with H.C. Wainwright & Co. LLC as lead manager.
